31st Congress of the European Committee for Treatment and Re
ECTRIMS 2015 "is one of the most important and powerful concentrations of MS professionals world-wide and constitutes a chance for bottomline networking and collaboration opportunities." The conference will be "a four-day vibrant and intensive scientific meeting with many learning opportunities in every current aspect of MS."
Q&A With Helen Tremlett From the University of British Columbia: Gut Microbiome And Its Role In Multiple Sclerosis
Q&A With June Halper From CMSC: Taking Global Lessons To Improve Multiple Sclerosis Care Worldwide And At Home
Q&A With Deborah Miller From Cleveland Clinic: Measuring Quality of Life Issues In Patients With Multiple Sclerosis
Q&A With Kate Dawson From Biogen: Tecfidera Continues To Show Positive Results For Multiple Sclerosis Patients
Q&A With Paulo Fontura From Roche: Ocrelizumab Shows First Signs of Promise For Patients With Primary Progressive Multiple Sclerosis
Q&A With Bernd Kieseier From Biogen: MS Paths Looks To Streamline Multiple Sclerosis Treatment For Doctors, Patients
Q&A With Luca Prosperini From Sapienza University: Improving Multiple Sclerosis Treatment Through Medication And Video Games
Q&A With Carrie Lyn Sammarco From NYU Langone Medical Center: Addressing Quality of Life Issues With Multiple Sclerosis Through Medication And The Benefits of Teamwork
Just as overactive bladder issues and constipation are an issue for patients with multiple sclerosis, mirabegron is a popular medication in the general population for managing these issues. At the NYU Langone Medical Center Comprehensive Care Center patients receive treatment from a wide variety of healthcare professionals in order to get the best results possible for their condition.
Q&A With Arman Eshaghi From University College London: Looking For Tools In Fight Against Memory Loss in Multiple Sclerosis
Q&A With Diego Cadavid From Biogen: Continuing to Research Optic Neuritis and Cognitive Impairment Treatments
Optic neuritis is linked to multiple sclerosis and a treatment to help patients with this condition continues to work its way through the research and approval process. Unlike other areas of multiple sclerosis treatment there is no singular way to measure or determine cognitive impairment in patients.
Q&A With Pers Sorensen From Copenhagen University: ECTRIMS Grows As Treatment Options For Multiple Sclerosis Expands
Q&A With John DeLuca From the Kessler Foundation: Testing and Diagnosing Cognitive Impairment Key in Multiple Sclerosis Treatment
Q&A With Jeffrey Cohen From Cleveland Clinic: ECTRIMS Provides Global View of Multiple Sclerosis Today And In the Future
For patients with multiple sclerosis (MS), disturbances in the thermoregulation can result in episodic hypothermia. It's believed that this is caused by hypothalamic lesions from the disease, however, the specifics are not fully understood. M. Toledano and colleagues from the University of Utah set out to uncover more in a poster session that will be presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.
Katarina Fink, an associate in the Department of Clinical Neuroscience at the Karolinska Institutet in Sweden, and colleagues analyzed the influence that multiple sclerosis (MS) has on a woman's fertility â€“ an area that has remained unclear. The findings will be described in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.
Q&A With Mark Freedman From the University Ottawa: Longterm Studies of Aubagio Continue to Show Safety for Multiple Sclerosis Treatment
Q&A With Barry Singer From Missouri Baptist Medical Center: Survey Looks at Multiple Sclerosis Treatment Beyond the Symptoms
Magnetic resonance imaging (MRI) can be used to identify lesions in the central nervous system in patients with multiple sclerosis (MS), but not all patients with active disease have identifiable lesions, and researchers are mixed over the extent to which lesions can be used as a marker for MS disease activity.
Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) is effective at lowering disease activity long-term in patients with relapsing-remitting multiple sclerosis (RRMS), according to Eva Havrdova, MD, of Charles University of Prague. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.
When it comes to treating and studying multiple sclerosis, the correlation between magnetic resonance imaging (MRI) lesions and actual disease activity has been widely disputed. A new analysis says that using MRI lesions as a proxy for disease activity is a sufficient approach when determining primary endpoints in clinical trials.
Delayed-release dimethyl fumarate (DMF) proved to be safe and effective in two phase 3 studies, DEFINE and CONFIRM, for patients with relapsing-remitting multiple sclerosis (RRMS). Gavin Giovannoni, MBBCh, PhD, FRCP, FRCPath, of the Queen Mary University of London and colleagues took a more detailed look to verify the data.
Alemtuzumab is an effective strategy to prevent relapses and other disease activity associated with multiple sclerosis (MS), according to Heinz Wiendl, MD, a professor at the University of MÃ¼nster. The research will be explained in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.
Race and vitamin D levels may play a crucial role in the risk of multiple sclerosis (MS), according to Annette M. Langer-Gould, MD, PhD, of Kaiser Permanente in Pasadena, California. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.